Navigation Links
Doyle, Kind call for higher renewable fuel standard
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Doyle Kind call for higher renewable fuel standard

(Date:11/19/2009)...ire-FirstCall/ -- Omeros Corporation (Nasdaq: OME...r the third quarter ended September 30, 2009. For ...reported a net loss of $3.9 million, or $1.34 per ...or $2.54 per share, for the same period in 2008. F...ompany reported a net loss of $15.5 million, or $5...
(Date:11/19/2009)...HAM, Mass., Nov. 19 Arlington Medi...at the leading driver of antibiotic selection in n...tivity against gram-positive and gram-negative pat...ause nosocomial pneumonia, surveyed European physi...hat provide appropriate coverage against common pa...
(Date:11/19/2009)... honored by latest award for revolutionary hearing...) November 16, 2009 -- Popular Science Magazine ha...aid from InSound Medical a winner of its coveted B...ry.    Chosen from thousands o...e hearing canal for up to four months while provid...
(Date:11/18/2009)...-dotted postage stamp that can sniff out poisonous... , As reported in the Sept. 13 issue of the jour...am at the University of Illinois have developed an...c industrial chemicals (TICs) that is simple, fast... This sensor array could be useful in detecting hi...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
...IGH, N.C., Sept. 10 ,Clinsys Clinical Research, In...ganization, today announced the appointments of Ra...al Biostatistics and Christopher,Gregory, Ph.D as ...e Drs. Srinivasan and Gregory, both highly,experie...linical research,join the Clinsys team," said Davi...
...ll Tomorrow (Tuesday) at 8:30 am EDT to ...ttage, NEW YORK, September 10 XTL,Biopharmaceutic...ay announced,the initiation of a Phase IIb clinica...rine reuptake inhibitor (SNRI) - for the treatment...g developed for the treatment of diabetic neuropat...
...member of the,Sigma-Aldrich Group (Nasdaq: SIAL )...to increase cGMP commercial-scale Active Pharmaceu... its SAFC Pharma(TM), Arklow, Ireland,facility, an...ations at its,Buchs, Switzerland facilities. Sche...ent will increase,production capacity and capabili...
Other Biology Technology:Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs 2Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs 3Clinsys Clinical Research, Inc. Announces Key Hires, Rajagopalan Srinivasan, Ph.D, to Strengthen Global Biostatistics Service Offering and Christopher Gregory, Ph.D, to Scientific Affairs 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment 2SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment 3
(Date:11/20/2009)...n . , In the current online issue of the Jo...rich and Dr. Kilian Eyerich together with their co... Dermopatico dell,Immacolata in Rome, present thei...one on the way to developing new treatment methods...and allergic reactions and potentially also allerg...
(Date:11/20/2009)...Center (ERC) has been awarded a grant from the U.S... recovering and reusing the heat that would be gen...rocess in a carbon capture system. The goal of the...and sequestration, or storage (CCS), and thus limi...nto the atmosphere by coal-fired power plants. , ...
(Date:11/19/2009)...t the end of the last ice age, North America,s vas...ic creatures as mammoths, mastodons, camels, horse...ecipitous slide to extinction. , And when their ...ty of large animals equaled or surpassed Africa,s ...irely novel ecosystem emerged as broadleaved trees...
Breaking Biology News(10 mins):Discovery of new type of immune cells regulating inflammation in chronic diseases 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3As Fire Ants Continue to Proliferate Hospital Proven Burn Anesthetic Brings Instant Relief for Bites Stings 50584 1As Fire Ants Continue to Proliferate Hospital Proven Burn Anesthetic Brings Instant Relief for Bites Stings 50584 2New Mexico Supreme Court Ruling Enhances Air Ambulance Safety 50580 1New Mexico Supreme Court Ruling Enhances Air Ambulance Safety 50580 2New Jersey Leaders Detail Savings for Health Reform 50576 1New Jersey Leaders Detail Savings for Health Reform 50576 2New Jersey Leaders Detail Savings for Health Reform 50576 3New Jersey Leaders Detail Savings for Health Reform 50576 4
...lif., March 4 /PRNewswire-FirstCall/,-- Phoenix Te...oration,(Nasdaq: ATML ) today announced the integ... solutions in Phoenix FailSafe(TM) and SecureCore,...http://www.newscom.com/cgi-bin/prnh/20070410/SFTU0...tween the two industry leaders,provides for signif...
...8 -- A destructive spring freeze that chilled the ...s the threat a warming climate poses to plants and... journal BioScience. The study was led by a team f...Laboratory. , The "Easter freeze" of April 5-9, 2...ng out young and tender sprouts two to three weeks...
... German . , What appear under an atomic force m...g are actually nanoscopic rings made of double-str... single-stranded fragment. As Michael Famulok and ...lain in the journal Angewandte Chemie , this gap i...potential to transform the rings into versatile na...
Other Biology News:Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs 2Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs 3Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs 4Killer freeze of '07 illustrates paradoxes of warming climate 2Nanorings 2
Mouse Anti-IFNA2 Monoclonal Antibody, Unconjugated, Clone 1F11 from Abnova Corporation
Mouse Anti-Human STAU2 Monoclonal Antibody, Unconjugated, Clone 6F9 from Abnova Corporation
Mouse Anti-Human NR2F2 Polyclonal Antibody, Unconjugated from Novus Biologicals
Mouse Anti-Human YARS Monoclonal Antibody, Unconjugated, Clone 2F3 from Abnova Corporation
Biology Products: